Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cymerus MSCs
- Development stage
- Phase 2
- Lead developer
- Cynata Therapeutics
- Modality
- iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous, Topical
01
Overview
Cymerus MSCs are a proprietary line of mesenchymal stem cells (MSCs) derived from induced pluripotent stem cells (iPSCs) using a scalable manufacturing process. Developed by Cynata Therapeutics, these cells are designed to overcome the limitations of traditional bone marrow-derived MSCs, such as donor variability and limited expansion potential. The Cymerus platform utilizes a single iPSC bank to produce a consistent and virtually limitless supply of MSCs. The lead product candidate, CYP-001, is being investigated for the treatment of graft-versus-host disease (GvHD), while other formulations like CYP-006TK (combined with a polymer-coated wound dressing) are targeting diabetic foot ulcers. The cells function by modulating the immune system and promoting tissue repair through the secretion of bioactive molecules.
- Brand names
- Cymerus
- Other names
- iPSC-derived mesenchymal stem cellsiMSCsCynata MSCs
Beyond the preview
Go deeper on Cymerus MSCs.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cymerus MSCs.